By Fineline Cube 
AbbVie Inc. (NYSE: ABBV) reported fourth‑quarter revenue of USD 16.618 billion, up 9.5% year‑on‑year (YOY), bringing full‑year 2025 revenue to USD 61.16 billion, an 8.5% YOY increase. The immunology portfolio was the primary growth driver, generating USD 30.406 billion (+14% YOY), led by Skyrizi (risankizumab) with USD 17.562 billion in sales (+49.7%).
Financial & Segment Performance Summary
| Segment | 2025 Revenue (USD B) | YOY Growth | Key Drivers |
|---|---|---|---|
| Immunology | 30.406 | +14% | Skyrizi (+49.7%), strong biologics demand |
| Neuroscience | 10.767 | +19.4% | Growth in migraine/psychiatry |
| Oncology | 6.655 | +1.4% | Steady performance |
| Aesthetics | 4.86 | -5.9% | Market softness |
| Eye Care | 2.109 | -5.5% | Competitive pressure |
Strategic Developments
Government Agreement & Investment:
- Reached U.S. government agreement for lower Medicaid prices
- Committed USD 100 billion in U.S. R&D and capital investments over next decade
- Secured tariff and pricing restriction exemptions for three‑year term
Manufacturing Expansion:
- Acquisition agreement with West Pharmaceutical Services for Tempe, Arizona device manufacturing facility and IP
- Supports production of existing and next‑generation immunology and neuroscience drugs
Pipeline Expansion:
- Exclusive licensing agreement with RemeGen Ltd (SHA: 688331, HKG: 9995) for PD‑1/VEGF bispecific antibody RC148
- Strengthens AbbVie’s oncology and immuno‑oncology portfolio
Forward‑Looking Statements
This brief contains forward‑looking statements regarding AbbVie’s revenue expectations, strategic initiatives, and commercial prospects. Actual results may differ due to competitive dynamics, regulatory changes, and market conditions.-Fineline Info & Tech